title: Complete response to short-term sorafenib treatment alone for hepatocellular carcinoma with bone, lymph node, and peritoneum metastases.
abstract: We report a 60-year-old male patient who developed extrahepatic metastases in bone, peritoneum, and lymph nodes (confirmed by computed tomography and positron emission tomography-computed tomography) after hepatectomy for hepatocellular carcinoma. He was treated with sorafenib (800 mg/day) but developed grade 3 hand-foot syndrome. He continued to be treated with sorafenib but at a lower dose (400 mg/week). The response to sorafenib therapy was graded as complete response at 6 months by the Response Evaluation Criteria in Solid Tumors. Sorafenib was continued for 8 months and the patient remained in complete response for 11 months. Further reporting of similar cases should help design treatment strategies and evaluate predictors of the response to sorafenib therapy.
authors.affiliation: Department of Medicine and Molecular Science, Division of Frontier Medical Science, and, Hiroshima University, Hiroshima, Japan.
authors.forename: Norihito
authors.initials: N
authors.lastname: Nakano
authors.affiliation: Department of Medicine and Molecular Science, Division of Frontier Medical Science, and, Hiroshima University, Hiroshima, Japan.
authors.forename: Tomokazu
authors.initials: T
authors.lastname: Kawaoka
authors.affiliation: Department of Medicine and Molecular Science, Division of Frontier Medical Science, and, Hiroshima University, Hiroshima, Japan.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Aikata
authors.affiliation: Department of Medicine and Molecular Science, Division of Frontier Medical Science, and, Hiroshima University, Hiroshima, Japan.
authors.forename: Fumi
authors.initials: F
authors.lastname: Honda
authors.affiliation: Department of Medicine and Molecular Science, Division of Frontier Medical Science, and, Hiroshima University, Hiroshima, Japan.
authors.forename: Yuki
authors.initials: Y
authors.lastname: Nakamura
authors.affiliation: Department of Medicine and Molecular Science, Division of Frontier Medical Science, and, Hiroshima University, Hiroshima, Japan.
authors.forename: Kei
authors.initials: K
authors.lastname: Morio
authors.affiliation: Department of Medicine and Molecular Science, Division of Frontier Medical Science, and, Hiroshima University, Hiroshima, Japan.
authors.forename: Masahiro
authors.initials: M
authors.lastname: Hatooka
authors.affiliation: Department of Medicine and Molecular Science, Division of Frontier Medical Science, and, Hiroshima University, Hiroshima, Japan.
authors.forename: Takayuki
authors.initials: T
authors.lastname: Fukuhara
authors.affiliation: Department of Medicine and Molecular Science, Division of Frontier Medical Science, and, Hiroshima University, Hiroshima, Japan.
authors.forename: Tomoki
authors.initials: T
authors.lastname: Kobayashi
authors.affiliation: Department of Medicine and Molecular Science, Division of Frontier Medical Science, and, Hiroshima University, Hiroshima, Japan.
authors.forename: Akira
authors.initials: A
authors.lastname: Hiramatsu
authors.affiliation: Department of Medicine and Molecular Science, Division of Frontier Medical Science, and, Hiroshima University, Hiroshima, Japan.
authors.forename: Michio
authors.initials: M
authors.lastname: Imamura
authors.affiliation: Department of Medicine and Molecular Science, Division of Frontier Medical Science, and, Hiroshima University, Hiroshima, Japan.
authors.forename: Yoshiiku
authors.initials: Y
authors.lastname: Kawakami
authors.affiliation: Department of Medicine and Molecular Science, Division of Frontier Medical Science, and, Hiroshima University, Hiroshima, Japan.
authors.forename: Shoichi
authors.initials: S
authors.lastname: Takahashi
authors.affiliation: Department of Medicine and Molecular Science, Division of Frontier Medical Science, and, Hiroshima University, Hiroshima, Japan.
authors.forename: Kazuaki
authors.initials: K
authors.lastname: Chayama
keywords: bone metastasis; hepatocellular carcinoma; lymph node metastasis; peritoneum metastasis; sorafenib